• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

耐萘啶酸肠杆菌科细菌对新型喹诺酮类及其他抗菌药物的交叉耐药性。

Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.

作者信息

Piddock L J, Diver J M, Wise R

出版信息

Eur J Clin Microbiol. 1986 Aug;5(4):411-5. doi: 10.1007/BF02075696.

DOI:10.1007/BF02075696
PMID:3758052
Abstract

One hundred urine isolates Enterobacteriaceae screened for resistance to 30 micrograms nalidixic acid by disc diffusion test were examined by MIC determination for in vitro susceptibility to nalidixic acid, ciprofloxacin, enoxacin, gentamicin, nitrofurantoin, trimethoprim, cephalexin and ceftazidime. Those resistant to nalidixic acid and also gentamicin or a cephalosporin were further examined to determine the mechanism of resistance. Compared to the total urine isolates of Enterobacteriaceae from the same time period, this population as a whole was less susceptible to all antimicrobials tested except gentamicin. Strains that exhibited multiple resistance had the conventional mechanisms of resistance to those antimicrobials. No multiply resistant strains had a permeability barrier due to outer membrane protein alterations causing cross-resistance to chemically unrelated classes of antimicrobials.

摘要

通过纸片扩散法筛选出100株对30微克萘啶酸耐药的尿源肠杆菌科细菌,通过最低抑菌浓度(MIC)测定来检测其对萘啶酸、环丙沙星、依诺沙星、庆大霉素、呋喃妥因、甲氧苄啶、头孢氨苄和头孢他啶的体外敏感性。对萘啶酸以及庆大霉素或头孢菌素耐药的菌株进一步检测以确定耐药机制。与同一时期的全部尿源肠杆菌科细菌分离株相比,总体而言,该群体除对庆大霉素外,对所有测试抗菌药物的敏感性均较低。表现出多重耐药的菌株具有对这些抗菌药物的传统耐药机制。没有多重耐药菌株因外膜蛋白改变导致对化学结构不相关的抗菌药物类别产生交叉耐药而具有通透性屏障。

相似文献

1
Cross-resistance of nalidixic acid resistant Enterobacteriaceae to new quinolones and other antimicrobials.耐萘啶酸肠杆菌科细菌对新型喹诺酮类及其他抗菌药物的交叉耐药性。
Eur J Clin Microbiol. 1986 Aug;5(4):411-5. doi: 10.1007/BF02075696.
2
The comparative in-vitro activity of eight newer quinolones and nalidixic acid.八种新型喹诺酮类药物与萘啶酸的体外活性比较
J Antimicrob Chemother. 1986 Nov;18 Suppl D:1-20. doi: 10.1093/jac/18.supplement_d.1.
3
In-vitro activity of newer quinolones against aerobic bacteria.新型喹诺酮类药物对需氧菌的体外活性
J Antimicrob Chemother. 1986 Apr;17 Suppl B:29-39. doi: 10.1093/jac/17.suppl_b.29.
4
Resistance to ten different fluoroquinolone antibiotics following in vitro exposures to nalidixic acid.
Diagn Microbiol Infect Dis. 1987 Jan;6(1):77-9. doi: 10.1016/0732-8893(87)90118-0.
5
In vitro studies of S-25930 and S-25932, two new 4-quinolones.两种新型4-喹诺酮类药物S-25930和S-25932的体外研究
Eur J Clin Microbiol. 1986 Jun;5(3):303-10. doi: 10.1007/BF02017786.
6
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.诺氟沙星、环丙沙星、依诺沙星和萘啶酸对从住院感染患者中分离出的423株革兰氏阴性杆菌和葡萄球菌的体外比较活性。
J Antimicrob Chemother. 1986 Jan;17(1):63-7. doi: 10.1093/jac/17.1.63.
7
A laboratory assessment of ciprofloxacin and comparable antimicrobial agents.环丙沙星及类似抗菌药物的实验室评估
Eur J Clin Microbiol. 1984 Aug;3(4):328-32. doi: 10.1007/BF01977488.
8
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.头孢他啶,一种对假单胞菌有效的头孢菌素:体外抗菌活性评估,包括纸片扩散法药敏试验的建议。
J Antimicrob Chemother. 1981 Sep;8 Suppl B:187-211. doi: 10.1093/jac/8.suppl_b.187.
9
Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.依诺沙星、环丙沙星、阿米氟沙星、诺氟沙星和氧氟沙星对177株细菌分离株的抗菌活性比较
J Antimicrob Chemother. 1986 May;17(5):623-8. doi: 10.1093/jac/17.5.623.
10
Comparative in vitro activities of aztreonam, ciprofloxacin, norfloxacin, ofloxacin, HR 810 (a new cephalosporin), RU28965 (a new macrolide), and other agents against enteropathogens.氨曲南、环丙沙星、诺氟沙星、氧氟沙星、HR 810(一种新型头孢菌素)、RU28965(一种新型大环内酯类药物)及其他药物对肠道病原体的体外比较活性。
Antimicrob Agents Chemother. 1985 Mar;27(3):388-92. doi: 10.1128/AAC.27.3.388.

引用本文的文献

1
Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus.环丙沙星诱导铜绿假单胞菌和耐甲氧西林金黄色葡萄球菌对结构不相关抗生素产生低水平耐药性。
Antimicrob Agents Chemother. 1993 Jun;37(6):1289-96. doi: 10.1128/AAC.37.6.1289.
2
Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.环丙沙星:抗菌活性、药代动力学特性及治疗用途综述
Drugs. 1988 Apr;35(4):373-447. doi: 10.2165/00003495-198835040-00003.
3
Resistance to quinolones.

本文引用的文献

1
METHOD FOR THE DETECTION OF SIGNIFICANT BACTERIURIA IN LARGE GROUPS OF PATIENTS.检测大量患者显著菌尿症的方法。
J Clin Pathol. 1964 Sep;17(5):498-503. doi: 10.1136/jcp.17.5.498.
2
In vitro and in vivo activity of DL-8280, a new oxazine derivative.新型恶嗪衍生物DL-8280的体外和体内活性
Antimicrob Agents Chemother. 1982 Oct;22(4):548-53. doi: 10.1128/AAC.22.4.548.
3
Role of porin proteins OmpF and OmpC in the permeation of beta-lactams.孔蛋白OmpF和OmpC在β-内酰胺通透性中的作用。
Pharm Weekbl Sci. 1987 Dec 11;9 Suppl:S11-5. doi: 10.1007/BF02075252.
4
Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.依诺沙星。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1988 Jul;36(1):32-66. doi: 10.2165/00003495-198836010-00004.
5
In-vitro activity of lomefloxacin (SC-47111) and other quinolones.洛美沙星(SC - 47111)及其他喹诺酮类药物的体外活性。
Infection. 1989 May-Jun;17(3):165-7. doi: 10.1007/BF01644019.
6
Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.培氟沙星。对其抗菌活性、药代动力学特性及治疗用途的综述。
Drugs. 1989 May;37(5):628-68. doi: 10.2165/00003495-198937050-00003.
Antimicrob Agents Chemother. 1982 Dec;22(6):942-8. doi: 10.1128/AAC.22.6.942.
4
In-vitro activity of enoxacin (CL-919), a new quinoline derivative, compared with that of other antimicrobial agents.新喹啉衍生物依诺沙星(CL-919)的体外活性与其他抗菌剂的比较。
J Antimicrob Chemother. 1984 Mar;13(3):237-44. doi: 10.1093/jac/13.3.237.
5
A simple method for the identification of aminoglycoside-modifying enzymes.一种鉴定氨基糖苷类修饰酶的简单方法。
J Antimicrob Chemother. 1984 Oct;14(4):339-48. doi: 10.1093/jac/14.4.339.
6
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.新型萘啶酸类似物AM - 715的体外抗菌活性
Antimicrob Agents Chemother. 1980 Feb;17(2):103-8. doi: 10.1128/AAC.17.2.103.
7
Review of bacterial resistance--a challenge to the treatment of urinary infection.细菌耐药性综述——尿路感染治疗面临的挑战
J Antimicrob Chemother. 1984 May;13 Suppl B:1-7. doi: 10.1093/jac/13.suppl_b.1.
8
New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.与脱氧核糖核酸回旋酶活性相关的新的萘啶酸抗性突变
J Bacteriol. 1981 Nov;148(2):450-8. doi: 10.1128/jb.148.2.450-458.1981.
9
In vitro activity of CI-919 (AT-2266), an oral antipseudomonal compound.口服抗假单胞菌化合物CI-919(AT-2266)的体外活性
Antimicrob Agents Chemother. 1983 May;23(5):658-63. doi: 10.1128/AAC.23.5.658.
10
In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.新型喹啉衍生物Bay 09867与其他抗菌药物的体外活性比较。
Antimicrob Agents Chemother. 1983 Apr;23(4):559-64. doi: 10.1128/AAC.23.4.559.